2011
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA 2011, 305: 1873-1881. PMID: 21558518, PMCID: PMC5638042, DOI: 10.1001/jama.2011.593.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlgorithmsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreast NeoplasmsBridged-Ring CompoundsDisease-Free SurvivalDrug Resistance, NeoplasmFemaleForecastingGene Expression ProfilingGenes, erbB-2Genes, NeoplasmGenomicsHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProspective StudiesReceptors, EstrogenRiskTaxoidsConceptsDistant relapse-free survivalInvasive breast cancerBreast cancerGenomic predictorsD. Anderson Cancer CenterAnthracycline-based regimensER-negative subsetExcellent pathologic responseProspective multicenter studyRelapse-free survivalAbsolute risk reductionStandard cancer treatmentPredictors of responseIndependent validation cohortAnderson Cancer CenterNegative breast cancerCancer treatment strategiesSequential taxaneNeoadjuvant chemotherapyPreoperative chemotherapyPathologic responseWorse survivalEndocrine sensitivityER statusMulticenter study
2010
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez‐Angulo A, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers. Cancer 2010, 116: 5161-5167. PMID: 20665886, DOI: 10.1002/cncr.25269.Peer-Reviewed Original ResearchConceptsTrial Assigning Individualized OptionsRisk of recurrenceOncotype DXRecurrence scoreBreast cancerIntermediate riskGrade I/II tumorsLymph node-negative breast cancerNode-negative breast cancerStage I/IID. Anderson Cancer CenterOncotype DX breast cancerRisk estimatesIntermediate-risk populationEarly breast cancerRoutine clinical variablesHigh-risk groupOncotype DX testingAnderson Cancer CenterAdjuvant chemotherapyDistant recurrenceConsecutive patientsII tumorsClinicopathological variablesLobular carcinoma
2009
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. Journal Of Clinical Oncology 2009, 27: 4287-4292. PMID: 19667268, PMCID: PMC2744271, DOI: 10.1200/jco.2008.21.6887.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinEstrogen Receptor alphaFemaleFollow-Up StudiesHumansImmunohistochemistryKaplan-Meier EstimateMaleMicrotubule-Associated ProteinsMiddle AgedMultivariate AnalysisPaclitaxelPredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicReceptor, ErbB-2Tau ProteinsConceptsDisease-free survivalOverall survivalTau protein expressionTau expressionEndocrine therapyPaclitaxel chemotherapyClinical trialsHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionBetter disease-free survivalWorse disease-free survivalD. Anderson Cancer CenterPrimary breast cancer specimensCourses of doxorubicinHER2-positive statusHormone receptor positiveNational Surgical BreastAdjuvant endocrine therapyPercent of patientsProtein expressionGreater tumor sizeER-positive statusEstrogen receptor-positive statusLow histologic gradeAnderson Cancer CenterA specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients
Pusztai L, Rouzier R, Pusztai L, Ibrahim N. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients. Journal Of Clinical Oncology 2009, 27: 1028-1028. DOI: 10.1200/jco.2009.27.15_suppl.1028.Peer-Reviewed Original ResearchSubsequent brain metastasesBrain metastasesBreast cancer patientsTN tumorsSpecific nomogramCancer patientsBreast cancerMetastatic triple-negative breast cancer patientsTriple-negative breast cancer patientsD. Anderson Cancer CenterTN breast cancerMetastatic breast cancerAnderson Cancer CenterBM occurrenceMetastatic diseaseMetastatic nodesMetastatic BCInitial diagnosisMetastatic sitesNegative tumorsCancer CenterPreventive treatmentRetrospective analysisFatal eventsHistological characteristics
2006
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006, 107: 1459-1466. PMID: 16948128, DOI: 10.1002/cncr.22177.Peer-Reviewed Original ResearchConceptsResidual tumor sizeBreast conservation therapyNeoadjuvant chemotherapyBreast conservation surgeryBreast cancer patientsTumor sizeConservation therapyBreast conservationConservation surgeryCancer patientsAnthracycline-based neoadjuvant chemotherapyD. Anderson Cancer CenterPaclitaxel neoadjuvant chemotherapyPreoperative chemotherapy regimenPreoperative chemotherapy regimensSuccessful conservative surgeryValidation of nomogramsInstitut Gustave RoussyAnderson Cancer CenterLogistic regression modelsChemotherapy regimenChemotherapy regimensConservative surgeryClinicopathologic dataCancer Center
2005
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
Lajos P, Symmans F, Hortobagyi G. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005, 12: 73-85. PMID: 15858436, DOI: 10.1007/bf02966817.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual MeetingDevelopment of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer
Pusztai L, Symmans FW, Hortobagyi GN. Development of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer. Breast Cancer 2005, 12: 73-85. DOI: 10.2325/jbcs.12.73.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual Meeting